Aura Biosciences Files 8-K
Ticker: AURA · Form: 8-K · Filed: Sep 12, 2024 · CIK: 1501796
| Field | Detail |
|---|---|
| Company | Aura Biosciences, INC. (AURA) |
| Form Type | 8-K |
| Filed Date | Sep 12, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Aura Biosciences filed an 8-K, but the key details are missing from this snippet.
AI Summary
Aura Biosciences, Inc. filed an 8-K on September 12, 2024, to report on other events and financial statements. The filing does not contain specific financial figures or details about the 'other events' in the provided text.
Why It Matters
This filing indicates Aura Biosciences is making a regulatory submission, but the specific details of the events or financial statements are not disclosed in this excerpt.
Risk Assessment
Risk Level: low — The filing is a standard 8-K without immediate disclosed financial impact or significant corporate changes in the provided text.
Key Players & Entities
- Aura Biosciences, Inc. (company) — Registrant
- 001-40971 (company) — Commission File Number
- 32-0271970 (company) — IRS Employer Identification No.
- 80 Guest Street (company) — Principal Executive Offices Address
- Boston (company) — City of Principal Executive Offices
- Massachusetts (company) — State of Principal Executive Offices
- 02135 (company) — Zip Code of Principal Executive Offices
- 617 500-8864 (company) — Registrant's Telephone Number
FAQ
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported is September 12, 2024.
What is the state of incorporation for Aura Biosciences, Inc.?
Aura Biosciences, Inc. is incorporated in Delaware.
What is the SIC code for Aura Biosciences, Inc.?
The Standard Industrial Classification (SIC) code is 2836, for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
What is the filing date of this 8-K report?
The filing date is September 12, 2024.
What are the principal executive offices of Aura Biosciences, Inc.?
The principal executive offices are located at 80 Guest Street, Boston, Massachusetts, 02135.
Filing Stats: 1,259 words · 5 min read · ~4 pages · Grade level 15.3 · Accepted 2024-09-12 06:50:35
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value per share AURA The Nasdaq
Filing Documents
- d886516d8k.htm (8-K) — 32KB
- d886516dex991.htm (EX-99.1) — 16KB
- d886516dex992.htm (EX-99.2) — 44KB
- g886516ex99_2p10g1.jpg (GRAPHIC) — 353KB
- g886516ex99_2p11g1.jpg (GRAPHIC) — 249KB
- g886516ex99_2p12g1.jpg (GRAPHIC) — 371KB
- g886516ex99_2p13g1.jpg (GRAPHIC) — 273KB
- g886516ex99_2p14g1.jpg (GRAPHIC) — 383KB
- g886516ex99_2p15g1.jpg (GRAPHIC) — 221KB
- g886516ex99_2p16g1.jpg (GRAPHIC) — 232KB
- g886516ex99_2p17g1.jpg (GRAPHIC) — 217KB
- g886516ex99_2p18g1.jpg (GRAPHIC) — 341KB
- g886516ex99_2p19g1.jpg (GRAPHIC) — 304KB
- g886516ex99_2p1g1.jpg (GRAPHIC) — 315KB
- g886516ex99_2p20g1.jpg (GRAPHIC) — 366KB
- g886516ex99_2p21g1.jpg (GRAPHIC) — 243KB
- g886516ex99_2p22g1.jpg (GRAPHIC) — 225KB
- g886516ex99_2p23g1.jpg (GRAPHIC) — 302KB
- g886516ex99_2p24g1.jpg (GRAPHIC) — 252KB
- g886516ex99_2p25g1.jpg (GRAPHIC) — 170KB
- g886516ex99_2p26g1.jpg (GRAPHIC) — 310KB
- g886516ex99_2p27g1.jpg (GRAPHIC) — 268KB
- g886516ex99_2p28g1.jpg (GRAPHIC) — 288KB
- g886516ex99_2p29g1.jpg (GRAPHIC) — 231KB
- g886516ex99_2p2g1.jpg (GRAPHIC) — 691KB
- g886516ex99_2p30g1.jpg (GRAPHIC) — 213KB
- g886516ex99_2p31g1.jpg (GRAPHIC) — 324KB
- g886516ex99_2p32g1.jpg (GRAPHIC) — 447KB
- g886516ex99_2p33g1.jpg (GRAPHIC) — 288KB
- g886516ex99_2p3g1.jpg (GRAPHIC) — 299KB
- g886516ex99_2p4g1.jpg (GRAPHIC) — 260KB
- g886516ex99_2p5g1.jpg (GRAPHIC) — 178KB
- g886516ex99_2p6g1.jpg (GRAPHIC) — 341KB
- g886516ex99_2p7g1.jpg (GRAPHIC) — 408KB
- g886516ex99_2p8g1.jpg (GRAPHIC) — 170KB
- g886516ex99_2p9g1.jpg (GRAPHIC) — 302KB
- 0001193125-24-217619.txt ( ) — 13785KB
- aura-20240912.xsd (EX-101.SCH) — 3KB
- aura-20240912_lab.xml (EX-101.LAB) — 18KB
- aura-20240912_pre.xml (EX-101.PRE) — 11KB
- d886516d8k_htm.xml (XML) — 4KB
Forward Looking Statements
Forward Looking Statements
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release Dated September 12, 2024. 99.2 Corporate Presentation of the Company. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aura Biosciences, Inc. Date: September 12, 2024 By: /s/ Julie Feder Julie Feder Chief Financial Officer